/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
- Mind Cure Health Inc. announced that its common shares will resume trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol “MCUR”
- The company also announced that it has granted an aggregate of 4,175,000 stock options to independent consultants
VANCOUVER, BC, Sept. 21, 2020 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation“), a mental health and wellness company with a mission to identify, develop and commercialize products that enhance mental health and wellness, ease suffering and increase productivity, is pleased to announce that, further to its news release dated September 17, 2020, its common shares will resume trading on the Canadian Securities Exchange (“CSE“) under the ticker symbol “MCUR” effective September 21, 2020.
Mind Cure’s common shares were listed on the CSE effective September 17, 2020 and halted pending the completion of its initial public offering.
This is a significant event in the Company’s history and we are looking forward to expeditiously build our senior operational and product management team, enhance and accelerate our marketing plan, and expedite our efforts to identify and evaluate new potential product candidates in addition to our Moonbeam Mushrooms product line.”Philip Tapley – Mind Cure Health Inc. President
The Company also announces that it has granted an aggregate of 4,175,000 stock options under its incentive stock option plan (the “Plan“) to independent consultants. The stock options are exercisable at a price of $0.25 and subject to the terms of the Plan.
About Mind Cure Health Inc.
Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure. Mind Cure’s initial products are a branded line of organic mushroom nootropics.
On Behalf of the Board of Directors
Philip Tapley, Chairman, President, and CEO
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the timing of the resumption of trading of common shares on the CSE and the trading symbol of the Shares on the CSE..
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no material change will occur before trading resumes on the CSE; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.